WDB coco Co

WDB coco Co Rule of 40

The Rule of 40 of WDB coco Co (7079.T) as of Oct 27, 2026 is 10.28 %. In the previous year, Rule of 40 was 40.43 % — a change of -74.56% (lower).

Rule of 40

10.28 %

YoY

-74.56%

Last updated:

Rule of 40 of WDB coco Co is 2026 10.28 % . Rule of 40 of WDB coco Co was 2025 40.43 % . It decreases by -74.56% lower compared to the previous year.

The WDB coco Co Rule of 40 history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Rule of 40
Date
Rule of 40
Jan 1, 2019
40.45 JPY
Jan 1, 2020
49.00 JPY
Jan 1, 2021
32.89 JPY
Jan 1, 2022
67.28 JPY
Jan 1, 2023
39.27 JPY
Jan 1, 2024
40.60 JPY
Jan 1, 2025
40.43 JPY
Jan 1, 2026
10.28 JPY
The WDB coco Co Rule of 40 history
YEARRule of 40YoY
10.28 %-74.56%
40.43 %-0.41%
40.60 %+3.38%
39.27 %-41.63%
67.28 %+104.58%
32.89 %-32.88%
49.00 %+21.14%
40.45 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

WDB coco Co Stock analysis

What does WDB coco Co do? WDB coco Co., Ltd. generates revenue through safety information management services, document support services, development support services, and clinical development support services. The company acts as an agent and support provider for drug development, offering input, evaluation, drafting, and reporting for safety information. Document support services cover QC, translation, and creation of CTD applications for PMDA approval. Development support includes survey form management, document filing, and call center operations. Clinical development support handles clinical trial-related tasks. The primary customers are pharmaceutical companies requiring regulatory compliance and efficient drug development processes. The company serves pharmaceutical firms needing assistance with safety data management, regulatory document preparation, and clinical trial support. Its services are tailored to meet PMDA requirements for marketing approval, particularly through CTD applications. The document support service specifically targets the creation and translation of materials for PMDA submissions. Development support services are utilized by clients managing clinical surveys and trial documentation. Clinical development support is contracted by pharmaceutical companies conducting clinical trials. WDB coco Co., Ltd. provides end-to-end support for drug development lifecycle, from safety data handling to clinical trial management. Its safety information management service is integral for regulatory submissions, while document support ensures compliance with PMDA standards. Development and clinical support services streamline trial operations, reducing time-to-market for pharmaceutical products. The company’s revenue streams are directly tied to the demand for regulatory and clinical support in the pharmaceutical industry. WDB coco Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about WDB coco Co stock

Rule of 40 of WDB coco Co is 10.28 % in 2026.

On Eulerpool you can find the complete historical development of Rule of 40 WDB coco Co since 2006 – with annual values, charts, and detailed analysis.

The Rule of 40 states that a company's revenue growth rate plus profit margin should exceed 40%. It is widely used to evaluate SaaS and high-growth companies.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — WDB coco Co

All Key Metrics — WDB coco Co